Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic
January 8, 2024
Category: Press Releases
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic
January 8, 2024
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic
January 8, 2024
The Yacht Club de Monaco celebrates another anniversary year
The Yacht Club de Monaco celebrates another anniversary year MONACO, Jan. 05, 2024 (GLOBE NEWSWIRE)
January 5, 2024
Constellation Brands Reports Third Quarter Fiscal 2024 Financial Results
VICTOR, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ), a leading
January 5, 2024
Constellation Brands Announces Wine & Spirits Leadership Transition
Robert Hanson to Step Down as EVP & President, Wine & Spirits Division Effective February
January 5, 2024